Maria Iuorno, MD
Endocrinology, Diabetes & Metabolism · Tappahannock, VANPI 1497752927
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,250 of the $20,413 with a category attached, or 64.9%. 19 manufacturers reported payments, led by Boehringer Ingelheim at 58.0% of the total. Reporting peaked in 2019 at $12,979 and has fallen 98.4% since, to $213 in 2024. Among endocrinology, diabetes & metabolism clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $318.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$12K
- Lilly USA, LLC$7K
- Tandem Diabetes Care, Inc.$332
- Amgen$303
- Novo Nordisk$193
- Dexcom, Inc.$174
- plus $422 from 13 others
What the payments were for
- Consulting fees$3,60018%
- Speaking & faculty fees$13,25065%
- Travel & lodging$1,7008%
- Food & beverage$1,8559%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 22 | $11,839 |
| Lilly USA, LLC | 8 | $7,149 |
| Tandem Diabetes Care, Inc. | 2 | $332 |
| Amgen(2 entities) | 4 | $303 |
| Novo Nordisk | 6 | $193 |
| Dexcom, Inc. | 4 | $174 |
| Sanofi-aventis U.S. LLC | 3 | $161 |
| Abbott | 2 | $42 |
| Antares Pharma, Inc. | 2 | $39 |
| AstraZeneca | 2 | $35 |
| Shire North American Group Inc | 1 | $21 |
| Valeritas, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| AbbVie | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Medtronic | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$18,518
- t-slim insulin pump$250
- DEXCOM G7 GSS (161)$135
- TZIELD$125
- TEPEZZA$111
- Wegovy$109
- EVENITY$102
How this compares
$20,413 in reported general payments places this provider in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 148 | $139,376 |
| OzempicSemaglutide | 97 | $136,736 |
| TrulicityDulaglutide | 75 | $90,523 |
| GlyxambiEmpagliflozin/Linagliptin | 36 | $43,141 |
| MounjaroTirzepatide | 39 | $38,634 |
| JanuviaSitagliptin Phosphate | 46 | $37,145 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $37,117 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 43 | $34,028 |
| TradjentaLinagliptin | 48 | $27,795 |
| Humalog Kwikpen U-100Insulin Lispro | 52 | $21,542 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $20,036 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $13,419 |
| SynthroidLevothyroxine Sodium | 142 | $11,709 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 65 | $10,215 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $8,323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $11,839 | $210,312232 claims |
| Novo NordiskOzempic | $193 | $136,73697 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $7,149 | $129,157114 claims |
| MerckJanuvia, Janumet Xr | $11 | $71,17389 claims |
| AbbVieSynthroid | $18 | $11,709142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Tappahannock
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
- Allen BurrisPowhatan$261K
- Samim EnayatFairfax$217K
- Denise ArmelliniFairfax$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.